摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

D-quinovose | 551-63-3

中文名称
——
中文别名
——
英文名称
D-quinovose
英文别名
6-Desoxy-α-D-glucopyranose;6-Desoxy-α-D-glucose;D-glucomethylose;alpha-D-Quinovopyranose;(2S,3R,4S,5S,6R)-6-methyloxane-2,3,4,5-tetrol
D-quinovose化学式
CAS
551-63-3
化学式
C6H12O5
mdl
——
分子量
164.158
InChiKey
SHZGCJCMOBCMKK-DVKNGEFBSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -2.1
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    90.2
  • 氢给体数:
    4
  • 氢受体数:
    5

SDS

SDS:ca1805e8e90ecc2392118443706cac89
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    D-quinovose 在 chromium dichloride 、 甲醇4-二甲氨基吡啶 、 sodium tetrahydroborate 、 三乙胺4-甲基-2-戊酮氯化(1-丁基-3-甲基咪唑) 、 nickel dichloride 作用下, 反应 3.0h, 生成 2,5-二甲基呋喃
    参考文献:
    名称:
    迈向改进的生物精炼技术:5-甲基糠醛可作为多功能的C6平台用于生物燃料开发
    摘要:
    低化学稳定性和高氧含量限制了在生物燃料开发中利用基于生物的平台化学物质5-(羟甲基)糠醛(HMF)。在这项工作中,路易斯酸催化可再生6-脱氧糖的转化导致形成更稳定的5-甲基糠醛(MF),具有很高的选择性。除了具有更高的稳定性外,MF还是HMF的脱氧类似物,具有更高的C / O比。描述了在温和条件下以MF为起始原料的高选择性合成新型液态生物燃料2,5-二甲基呋喃的方法。证明了MF相对于HMF在苯偶姻和醛醇缩合反应中可产生长链烷烃前体的优异合成效用。
    DOI:
    10.1002/cssc.201802126
  • 作为产物:
    描述:
    cyanogriside F 在 盐酸 作用下, 反应 3.0h, 以90%的产率得到D-quinovose
    参考文献:
    名称:
    Acyclic Congeners from Actinoalloteichus cyanogriseus Provide Insights into Cyclic Bipyridine Glycoside Formation
    摘要:
    Inactivation of the O-methyltransferase gene crmM of Actinoalloteichus cyanogriseus WH1-2216-6 led to a mutant that produced three new acyclic bipyridine glycosides, cyanogrisides E-G (1-3). Further chemical analysis of the wild strain yielded 1 and another new analogue, cyanogriside H (4). Compounds 1-4 possess a skeleton consisting of a 2,2'-bipyridine and a d-quinovose or l-rhamnose sugar moiety. Cyanogriside G (3) was considered to be a key biosynthetic intermediate of the cyclic bipyridine glycosides cyanogrisides A-D. Compounds 2 and 3 showed cytotoxicities against HCT116 and HL-60 cells, and compounds 1 and 4 were cytotoxic on K562 cells.
    DOI:
    10.1021/ol5019757
点击查看最新优质反应信息

文献信息

  • [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
    申请人:CIDARA THERAPEUTICS INC
    公开号:WO2018006063A1
    公开(公告)日:2018-01-04
    Compositions and methods for the treatment of bacterial infections include compounds containing dimers of cyclic heptapeptides conjugated to one or more monosaccharide or oligosaccharide moieties. In particular, compounds can be used in the treatment of bacterial infections caused by Gram-negative bacteria.
    用于治疗细菌感染的组合物和方法包括含有环七肽二聚体与一个或多个单糖或寡糖基团结合的化合物。特别是,这些化合物可用于治疗由革兰氏阴性细菌引起的细菌感染。
  • CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
    申请人:Alnylam Pharmaceuticals, Inc.
    公开号:US20160051691A1
    公开(公告)日:2016-02-25
    The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.
    本发明提供了包含至少一个式(I)的亚单位的iRNA试剂: 其中: A和B分别独立于每次出现O、N(RN)或S; X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R; R是LG、-连接子-LG,或具有下面所示结构: LG独立于每次出现的是一种碳水化合物,例如,单糖、双糖、三糖、四糖、寡糖、多糖; RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基; Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
  • [EN] COMPOSITIONS AND METHODS FOR TARGETING METASTATIC TUMORS USING MULTIVALENT LIGAND-LINKED CARBOHYDRATE POLYMERS<br/>[FR] COMPOSITIONS ET METHODES PERMETTANT DE CIBLER DES TUMEURS METASTATIQUES A L'AIDE DE POLYMERES MULTIVALENTS CARBOHYDRATES LIES A UN LIGAND
    申请人:PRO PHARMACEUTICALS INC
    公开号:WO2005092097A1
    公开(公告)日:2005-10-06
    Disclosed herein are compositions comprising a drug linked to a multivalent ligand polysaccharide and the use of this composition in the prevention and treatment of cancer. In one aspect, the polysaccharide is obtained by physical and chemical treatment of naturally occurring polymers or semi synthetic polymers which are bridged specifically with one or more anti-cancer chemotherapeutic agents. Another aspect is directed to the effective delivery of the polysaccharide together with the chemotherapeutic agent to diseased tissue including cancerous tissue.
    本文披露了包含药物与多价配体多糖相连的组合物,以及该组合物在预防和治疗癌症中的用途。在一个方面,该多糖是通过对天然聚合物或半合成聚合物进行物理和化学处理获得的,这些聚合物特异地与一个或多个抗癌化疗药物相桥接。另一个方面涉及将多糖与化疗药物有效地输送到包括癌组织在内的患病组织。
  • Medicament containing a sulfopyranosylacylglycerol derivative
    申请人:TOYO SUISAN KAISHA, LTD.
    公开号:US20020028776A1
    公开(公告)日:2002-03-07
    A medicament containing at least one compound selected from the group consisting of compounds represented by General formula (1): 1 wherein R 101 represents an acyl residue of an unsaturated higher fatty acid, and R 102 represents a hydrogen atom or an acyl residue of an unsaturated higher fatty acid, and pharmaceutically acceptable salts thereof, as an active ingredient.
    包含至少一种从以下组中选择的化合物的药物:由通用公式(1)表示的化合物组1其中,R101代表不饱和高级脂肪酸的酰基残基,R102代表氢原子或不饱和高级脂肪酸的酰基残基,以及药用可接受的盐作为有效成分。
  • [EN] 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES<br/>[FR] 4-BIARYLYL-1-PHÉNYLAZÉTIDIN-2-ONES
    申请人:MICROBIA INC
    公开号:WO2005047248A1
    公开(公告)日:2005-05-26
    4-Biarylyl-1-phenylazetidin-2-ones useful for the treatment of hypercholesterolemia are disclosed. The compounds are of a general formula (I) in which formula (II) represents an aryl or heteroaryl residue, Ar represents an aryl residue; U is a two to six atom chain; and the R’s represent substituents.
    4-双苯基-1-苯基氮杂环丁烷-2-酮,用于治疗高胆固醇血症的化合物被披露。这些化合物具有通用公式(I),其中公式(II)代表一个芳基或杂芳基残基,Ar代表一个芳基残基;U是2到6个原子的链;而R's代表取代基。
查看更多